4570 Immuno-Biological Laboratories
- 523
- +8+1.55%
Immuno-Biological Laboratories News
Investment strategy for today, June 21st.
[FISCO selected stocks] [Materials stocks] Cubic Net Holdings <6571> 1081 yen (6/20) The company operates hair cut specialty stores under brands such as QB HOUSE, QB PREMIUM, and FaSS. They announced that the end-of-year dividend (= annual dividend) estimate for the fiscal year ending June 2024 is 27 yen. The previous estimate was 22 yen, and the previous period was 20 yen. The company recognizes the return of profits to shareholders as an important management issue and secures retained earnings for investment in future growth.
Despite the downward pressure from softness and firmness in long-term US Treasury yields, the downside is expected to remain strong.
[Emerging market individual stock strategy] Today's emerging market is expected to have a sluggish trend. On the 20th, in the US stock market, the Dow Jones Average continued its 3-day rise, rising by 299.90 dollars (+0.77%) to 39,134.76 dollars. The rise in interest rates due to the decrease in new unemployment insurance claims was unpleasant and caused a drop in the morning. On the other hand, the number of new housing starts and the Philadelphia Fed Manufacturing Index showed a slowdown in the economy, and the expectation of a rate cut by the Federal Reserve Board supported the market. As for the Nasdaq, semiconductor shares continued to rise for several days.
PayCloud HD, Immunobiology Research Institute, and others.
<3987> Shimuks Initiative, which develops EcoMot IoT/DX services, has signed a basic agreement on a capital business partnership. <4015> PayCloud HD revises its performance forecast, with expected operating profit for this fiscal year at 270 million yen, up from 200 million yen. <4418> JDS Corporation revises its performance forecast, expecting operating profit for this fiscal year at 30 million yen, down from 120 million yen. <4570> Immune Bioscience Institute has entered into an exclusive license agreement for the implementation of antiserum gene for severe fever thrombocytopenic syndrome (SFTS) virus. <7078> IN.
Institute of Immunology Research: (Correction/numerical data correction) Partial correction of the "March 2024 term-end settlement report [Japan standard] (consolidated)."
The era of 5 million dementia patients has arrived, promising stocks and overall verification of social issues. <Stock Top Feature>
The second meeting of the conference for promoting dementia policies was held on May 8th, and it was estimated that the number of dementia patients would reach 5.231 million in 2030 (4.432 million in 2022). The "Basic Law on Dementia" was enacted in January of this year to realize a society in which people with dementia can live together, and discussions are underway to formulate a basic plan. However, to overcome the era of 5 million dementia patients, it is essential to utilize both policies and treatments, as well as technology. Therefore, this time, we focus on related stocks that confront social issues.
IMMUNO-BIOLOGICAL LABORATORIES: Financial results briefing materials for the fiscal year ending 2024/3 (42nd term)
IMMUNO-BIOLOGICAL LABORATORIES: Summary of Financial Results for the Fiscal Year Ending March 31, 2024 [Japanese GAAP] (Consolidated)
Immuno Biological Labs Sees FY Net Y115.00M
Immuno-Biological Laboratories Co. Ltd. also released the following forecasts: GROUP Year Ending Mar 2025 Revenue Y925.00 mln Operating Profit Y120.
Classicom, Confidence I, etc.
＜2351＞ASJ upward revision, previous fiscal year operating profit forecast 102 million yen ← 80 billion yen ＜3286＞Trust HD shareholder benefit plan newly established ＜3625＞ tech firm earnings forecast revision, current fiscal year sales forecast 5.00 billion yen ← 6.00 billion yen ＜3917＞formulating a medium-term management plan involving iRidge from the fiscal year ending 25/3 to the fiscal year ending 27/3 ＜4165＞ Played revised upward, sales forecast for the current fiscal year ending 10.809 billion yen ← 10.666 billion yen <43
IMMUNO-BIOLOGICAL LABORATORIES: Notice regarding revisions to full-year earnings forecasts
Backstage [stocks that moved, stocks that were made]
*Hello's ＜2742＞ 4500 +21524/2 earnings forecast revised upward. *Motorbike King ＜3377＞ 533-44 The operating profit and loss for the first quarter was in deficit of 613 million yen. *Fujikoshi ＜6474＞ 3375-120 1st quarter operating profit decreased 69.8%. *Truss OP ＜6696＞ 337 +80 The report “Marubeni Information Systems sells power consumption reduction solutions” was viewed as material. *BIRDMAN ＜7063＞ 1198 +54 Kao “SPOT
Institute for Immunobiology --- Significant backlash; joint acquisition of a patent for an antibody drug to diagnose and treat gastrointestinal stromal tumors with Tokushima University
Significant backlash. It has been announced that the University of Tokushima and the University of Tokushima have jointly obtained a patent (within Japan) relating to research and development of antibody pharmaceuticals to diagnose and treat GIST (gastrointestinal stromal tumors), which are a type of “sarcoma” derived from immature mesenchymal cells under the mucous membrane of the digestive tract wall of the stomach and intestines. The name of the invention is “c-Kit-positive tumor-specific antibody fragment”. There is currently no impact on the fiscal year ending 25/3, but it is said that if an event affecting business results occurs, it will be promptly disclosed.
4/5 [Today's Investment Strategy]
[FISCO Specially Selected Brand] [Material Brand] Onward Holdings ＜8016＞ 571 yen (4/4) apparel manufacturer. It will be developed under brands such as “23 wards,” “suite,” and “iCB.” Financial results for the fiscal year ending February 24 have been announced. Operating profit was 11.2 billion yen (2.1 times the previous fiscal year). Earnings for the previous fiscal year were revised upward on March 28. Operating profit for the fiscal year ending 25/2 is expected to be 12.5 billion yen (up 11.0% from the previous fiscal year). At the same time, a medium- to long-term management vision was announced. Operating profit was 16 billion yen for the fiscal year ending 27/2, 31
Weakness and depreciation of US stocks weigh heavily [Emerging Markets Individual Stock Strategy]
[Emerging Markets Individual Stock Strategy] Today's emerging markets are expected to develop softly. In the US stock market yesterday 4th, the Dow average continued to drop drastically for 4 days to 38596.98 dollars, which depreciated 530.16 dollars (-1.35%). The local morning time zone was strong, but in the afternoon, President Kashkari of the Minneapolis Fed mentioned the possibility that interest rate cuts would not be implemented if inflation improvements stagnated, and the tense situation in the Middle East was also wary, and after turning to a decline, the range of decline widened. Today's Emerging Markets
Institute for Immunobiology, Samantha JP, and others
＜4570＞Immunobiology Research Institute National University Corporation Tokushima University Corporation and Tokushima University jointly obtained a patent (within Japan) related to research and development of antibody pharmaceuticals to diagnose and treat GIST (gastrointestinal stromal tumors) derived from immature mesenchymal cells under the mucous membrane of the digestive tract wall of the stomach and intestines ＜7829＞Samantha JP earnings forecast revised, operating loss forecast for the current fiscal year △ 1,027 billion yen ←△ 10.50 billion yen
Check out the disclosed information for [Tomorrow's Good and Bad Materials]! (Announced on 4/4)
[Good news] ――――――――――■Qushim [Tokyo Stock Exchange S] will record a profit of 35 million yen from the sale of investment securities as special profit for the 2nd quarter of the fiscal year ending 24/10. ■eSupport Link [TSE S] The 12-2 fiscal year (1Q) accounts surged and landed in surplus. ■Adastria [Tokyo Stock Exchange P] Current account increased 3% to the highest profit for the 2nd consecutive term, and dividends for the first fiscal year increased by 5 yen, and dividends for the current fiscal year increased by 5 yen. ■McDonald's Holdings Japan
Analysis
Price Target
No Data
